Read by QxMD icon Read

Radioiodine therapy

Raj K Gopal, Kirsten Kübler, Sarah E Calvo, Paz Polak, Dimitri Livitz, Daniel Rosebrock, Peter M Sadow, Braidie Campbell, Samuel E Donovan, Salma Amin, Benjamin J Gigliotti, Zenon Grabarek, Julian M Hess, Chip Stewart, Lior Z Braunstein, Peter F Arndt, Scott Mordecai, Angela R Shih, Frances Chaves, Tiannan Zhan, Carrie C Lubitz, Jiwoong Kim, A John Iafrate, Lori Wirth, Sareh Parangi, Ignaty Leshchiner, Gilbert H Daniels, Vamsi K Mootha, Dora Dias-Santagata, Gad Getz, David G McFadden
Hürthle cell carcinoma of the thyroid (HCC) is a form of thyroid cancer recalcitrant to radioiodine therapy that exhibits an accumulation of mitochondria. We performed whole-exome sequencing on a cohort of primary, recurrent, and metastatic tumors, and identified recurrent mutations in DAXX, TP53, NRAS, NF1, CDKN1A, ARHGAP35, and the TERT promoter. Parallel analysis of mtDNA revealed recurrent homoplasmic mutations in subunits of complex I of the electron transport chain. Analysis of DNA copy-number alterations uncovered widespread loss of chromosomes culminating in near-haploid chromosomal content in a large fraction of HCC, which was maintained during metastatic spread...
August 13, 2018: Cancer Cell
Francoise Borson-Chazot, Emmanuelle Dantony, Frédéric Illouz, Jonathan Lopez, Patricia Niccoli, Johanna Wassermann, Christine Do Cao, Sophie Leboulleux, Marc Klein, Antoine Tabarin, Marie-Claude Eberlé, Danielle Benisvy, Christelle de la Fouchardiere, Claire Bournaud, Helene Lasolle, Armelle Delahaye, Muriel Rabilloud, Veronique Lapras, Myriam Decaussin-Petrucci, Martin Schlumberger
BACKGROUND: Dysregulation of the phosphatidylinositol 3-kinase (PI3K) pathway is frequent in advanced follicular (FTC) and poorly differentiated thyroid (PDTC) carcinomas and has been implicated in oncogenesis and tumor progression. This study investigated the efficacy and safety of buparlisib, a pan-PI3K inhibitor in radioiodine refractory FTC and PDTC. METHODS: Open-label, multicenter, phase II pilot study. The primary endpoint was progression free survival (PFS) at 6 months...
August 14, 2018: Thyroid: Official Journal of the American Thyroid Association
Douglas Van Nostrand
The management of aggressive and progressing metastatic differentiated thyroid cancer (DTC) is very difficult, and the determination as to when such patients are refractory to 131 I therapy (e.g. radioiodine refractory) is problematic and controversial. OBJECTIVE: The objective of this review is to discuss 1) the present major classifications of radioiodine refractory disease in DTC, 2) factors that should be considered before designating a patient's DTC as radioiodine refractory, 3) potential approaches and caveats to help manage and minimize a patient's exclusion from an 131I therapy that may have potential benefit in patients with aggressive and progressing metastatic DTC, 4) next steps for revision of the classifications of radioiodine refractory DTC, and 5) areas for future research...
August 14, 2018: Thyroid: Official Journal of the American Thyroid Association
Chae Moon Hong, Byeong-Cheol Ahn
Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully used for more than 70 years. However, there is still plenty of controversy surrounding the use and doses of radioiodine. There is insufficient evidence to answer the questions. Recent American Thyroid Association (ATA) guidelines seem to favor low-dose RAI, based on recent clinical trials and meta-analyses. However, long-term follow-up data remains limited, and there are additional factors we should consider that might affect the efficacy of RAI therapy...
August 2018: Nuclear Medicine and Molecular Imaging
Kequan Lou, Yushen Gu, Yan Hu, Siyang Wang, Hongcheng Shi
OBJECTIVE: In this study we aimed to evaluate the role of technetium-99m pertechnetate whole body scan (99m Tc WBS) with single photon emission tomography/computed tomography (SPET/CT) in detecting remnant thyroid tissue, nodal and distant metastases, in differentiated thyroid cancer (DTC) patients before radioiodine (131 I) therapy. SUBJECTS AND METHODS: A retrospective analysis was performed in 416 pathologically confirmed DTC patients with total/near-total thyroidectomy...
May 2018: Hellenic Journal of Nuclear Medicine
Margret Ehlers, Stephanie Allelein, Franziska Schwarz, Hubertus Hautzel, Anne Kuebart, Mathias Schmidt, Matthias Haase, Till Dringenberg, Matthias Schott
Circulating tumor cells (CTCs) have been shown to be a valuable prognostic marker for different solid cancers. Within the present study we quantified CTCs in thyroid cancer (TC) patients. Special focus was given to disease-free PTC patients with undetectable serum thyroglobulin (Tg) levels. Altogether, 67 TC patients (33 papillary, 20 follicular, 14 medullary) were included in the study. CTC numbers, which were normalized to 3.3×105 peripheral blood mononuclear cells, were correlated with clinical outcome...
August 2018: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
Wolfgang Roll, Burkhard Riemann, Michael Schäfers, Lars Stegger, Alexis Vrachimis
INTRODUCTION: Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have a rather poor prognosis and are in need of novel treatments. As RrDTCs can in some cases express somatostatin receptors (SSRT), targeting of these receptors by Ga/Lu-DOTATATE could evolve as a novel theranostic option. METHODS: Five RrDTC patients with limited further therapeutic options and documented expression of SSRT using Ga-DOTATATE-PET/CT received 2 to 4 cycles of PRRT with Lu-DOTATATE...
July 27, 2018: Clinical Nuclear Medicine
Moran Amit, Shorook Na'ara, Demilza Francis, Wisam Matanis, Sagit Zolotov, Birgit Eisenhaber, Frank Eisenhaber, Michal Weiler Sagie, Leonid Malkin, Salem Billan, Tomer Charas, Ziv Gil
Background: Radioactive iodine (RAI) is the mainstay of treatment for differentiated thyroid carcinoma (DTC). Nevertheless, the mechanism of RAI resistance that occurs in many patients with DTC remains unknown. We aimed to elucidate the role of post-translational regulation of radioiodine uptake. Methods: We analyzed the expression pattern of the ribosomal glycosylphosphatidylinositol transamidase (GPIT) complex in freshly excised tumors from 10 patients with DTC...
December 1, 2017: Journal of the National Cancer Institute
Tali Ofir Dovrat, Ethan Sokol, Garrett Frampton, Eliya Shachar, Sharon Pelles, Ravit Geva, Ido Wolf
INTRODUCTION: V600E BRAF mutation is an established driver mutation in a variety of tumors. Vemurafenib is a selective inhibitor of the BRAF V600E kinase, known to be highly effective in BRAF V600E-positive metastatic melanoma. As a single agent, vemurafenib is relatively ineffective in other V600E-positive malignancies. Case 1: A 72 year old man with metastatic CRC who failed several previous lines of chemotherapy. Genetic analysis of 315 cancer-related genes (Foundation Medicine, FMI) revealed a BRAF V600E mutation...
July 23, 2018: Cancer Biology & Therapy
Alex Khoo Cheen Hoe, Lee Yeong Fong, Fatin Nadhirah Abdul Halim, Quek Kia Fatt, Fadzilah Hamzah
Radioiodine (131I) therapy is the mainstay of treatment for patients who had undergone total thyroidectomy for well differentiated thyroid carcinoma. Increased fluid intake has always been encouraged to minimize the risk of non-target organ exposure to I-131radiation. This study aimed to determine the minimum amount of fluids needed for patients to have the fastest time to achieve permissible level for release after high dose I-131therapy. METHODOLOGY: All the patients who were treated with high dose I-131from 18th January 2016 till 31st December 2016 in Hospital Pulau Pinang, Malaysia were recruited...
July 2018: World Journal of Nuclear Medicine
Ewa Nowosinska, Pei San Chan, John R Buscombe
Radioimmunotherapy (RIT) has been available for some time to treat patients with non-Hodgkin's lymphoma, but its use in Hodgkin's lymphoma has been less available, partly because of the need to find an appropriate antibody. A new radioiodinated chimeric antibody directed against the CD25 epitope (131 I basiliximab) seems promising, but assessment of response has been difficult. 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET) has become a standard method by which the response of Hodgkin's disease to chemotherapy is both predicted and assessed with well-understood criteria of response...
July 2018: World Journal of Nuclear Medicine
Marie Alix Balay, Patrick Aidan, Marie Helene Schlageter, Odette Georges, Taly Meas, Maroun Bechara, Marie Elisabeth Toubert, Isabelle Faugeron, Herve Monpeyssen, Cécile N Chougnet
Objectives: Transaxillary robotic thyroidectomy surgery (TARS) has been reported to be a safe approach in patients with differentiated thyroid carcinoma, and oncological responses are promising. Study Design: This study aimed to evaluate the oncological outcomes of TARS followed by radioiodine (RAI) therapy in patients with differentiated thyroid carcinoma. Between 2011 and 2016, patients treated for differentiated thyroid carcinoma by TARS in a single institution, followed by RAI, were retrospectively included...
June 2018: European Thyroid Journal
Satoshi Koyama, Naritomo Miyake, Kazunori Fujiwara, Tsuyoshi Morisaki, Takahiro Fukuhara, Hiroya Kitano, Hiromi Takeuchi
Background: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has an anticancer action in patients with differentiated thyroid cancer that is refractory to radioiodine. Knowledge of the efficacy and safety of lenvatinib in patients with anaplastic thyroid cancer (ATC) is limited. Tyrosine kinase inhibitors frequently cause hypothyroidism, but the incidence of hypothyroidism with lenvatinib is unclear. Objectives: We conducted a retrospective study to investigate the efficacy and safety of lenvatinib in ATC...
June 2018: European Thyroid Journal
Jessica Castro de Vasconcelos, Icléia Siqueira Barreto, Patrícia Sabino Matos, Frederico Fernandes Ribeiro Maia, Marcos Antônio Tambascia, Maria Cândida Ribeiro Parisi, Denise Engelbrecht Zantut-Wittmann
To better understand the genesis of autoimmunity in Graves' disease (GD), it is essential to study the mechanism of apoptosis and cell proliferation in thyroid cells and intrathyroidal lymphocytic infiltrate of GD patients. Methods . A cross sectional, observational study performed by evaluating histopathological samples of thyroidectomy products from GD patients using immunohistochemistry. New histological sections were prepared for immunohistochemical analysis with markers of cell proliferation, antiproliferation, apoptosis, and antiapoptosis...
2018: International Journal of Endocrinology
Umit Eksioglu, Hasan Ikbal Atilgan, Mehmet Yakin, Nuray Yazihan, Ugur Emrah Altiparmak, Nihat Yumusak, Meliha Korkmaz, Ayten Demir, Firdevs Ornek, Pelin Aribal Ayral, Gokhan Koca
PURPOSE: To evaluate antioxidant effects of active vitamin D (calcitriol) against high-dose radioiodine (RAI) therapy-associated damage of lacrimal gland. MATERIALS AND METHODS: Wistar albino rats were used and divided into three groups randomly (n = 12/group). The first group was appointed as the negative control group and received no RAI or medication. The second group was appointed as the positive control group that only received 3 mCi/kg (111 MBq/kg) RAI via gastric gavage and the last group was the treatment group that received 3 mCi/kg RAI via same method and calcitriol (200 ng/kg/day) via intraperitoneal administration...
July 13, 2018: Cutaneous and Ocular Toxicology
Line Tang Møllehave, Allan Linneberg, Tea Skaaby, Nils Knudsen, Torben Jørgensen, Betina Heinsbæk Thuesen
Background: Long-term iodine exposure may influence the frequency of thyroid disease treatments through fluctuations in thyroid diseases. Yet, the long-term fluctuations in thyroid disease treatments upon iodine fortification (IF) are not fully known. We aimed to examine the development in thyroid disease treatments in Denmark before and following the implementation of IF in 2000. Methods: Nationwide data on antithyroid medication, thyroid hormone therapy, thyroid surgery, and radioiodine treatment were obtained from Danish registries...
2018: Clinical Epidemiology
Jindian Li, Chenyu Peng, Zhide Guo, Changrong Shi, Rongqiang Zhuang, Xingfang Hong, Xiangyu Wang, Duo Xu, Pu Zhang, Deliang Zhang, Ting Liu, Xinhui Su, Xianzhong Zhang
The purpose of this study is to develop a specific CXCR4-targeting radioiodinated agent (125 I- or 131 I-pentixather) for single-photon-emission-computed-tomography (SPECT) imaging of CXCR4 expression in myocardial-infarction-reperfusion (MI/R) rat models. After SPECT-CT imaging with 125 I-pentixather at 4, 12, and 36 h and 3 and 7 days after MI/R, the models were validated by ex vivo autoradiography, TTC staining, and immunohistochemistry and in vivo echocardiography and classical 99m Tc-MIBI perfusion imaging...
July 26, 2018: Analytical Chemistry
K Zhang, C Li, J Liu, X Tang, Z Li
BACKGROUND: Thyroid cancer is one of the most common endocrine malignancies. Although the 10-year survival rate of differentiated thyroid cancer (DTC) is about 90% after conventional treatments, a small proportion of patients still suffer from tumor recurrence or drug resistance. OBJECTIVE: This review article summarizes recent researches and clinical trials related to target drugs that reduce mortality in thyroid cancer. METHODS: This is a review of the recent literature and clinical trials on the three main aspects including methylation genes in thyroid cancers, the relationship between BRAF mutation and gene methylation, target and dehypermethylation drugs in clinical trials...
July 10, 2018: Journal of Endocrinological Investigation
Kaitlyn Vennard, Matthew P Gilbert
Thyroid storm is a rare endocrine emergency characterized by dysfunction of multiple organ systems. Thyroid storm is more common in Graves' disease and can be precipitated by surgery, trauma, infection, metabolic abnormalities, iodine load, and parturition. We present a diagnostically challenging case of thyroid storm precipitated by radioiodine therapy and accompanied by bradycardia, a rare but life-threatening complication related to treatment for hyperthyroidism.
2018: Case Reports in Endocrinology
Zhide Guo, Mei Chen, Chenyu Peng, Shiguang Mo, Changrong Shi, Guifeng Fu, Xuejun Wen, Rongqiang Zhuang, Xinhui Su, Ting Liu, Nanfeng Zheng, Xianzhong Zhang
Radiolabeled nanomaterials, especially those with ultra-small structures, have been the research focus in recent years, and thus may open up new prospects for clinical diseases theranostics. Herein, fluorinated Pd nanosheets labeled with Gd or radionuclides are developed as multimodal platforms for tumor theranostics. These nanomaterials decorated by functional polyethylene glycol demonstrate ultrahigh 19 F MRI signal, ultrasmall size and good dispersibility. These ultrasmall materials exhibit good biocompatibility and easily to be modified for multimodal imaging (SPECT/MRI/PAI) by assembling the functional groups like building blocks...
October 2018: Biomaterials
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"